Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to 32.37%.

  • Treace Medical Concepts' EBITDA Margin rose 12200.0% to 32.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.94%, marking a year-over-year increase of 72200.0%. This contributed to the annual value of 26.66% for FY2024, which is 2900.0% down from last year.
  • Treace Medical Concepts' EBITDA Margin amounted to 32.37% in Q3 2025, which was up 12200.0% from 36.73% recorded in Q2 2025.
  • Treace Medical Concepts' 5-year EBITDA Margin high stood at 0.87% for Q4 2024, and its period low was 57.51% during Q2 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 31.11% (2022), whereas its average is 28.21%.
  • In the last 5 years, Treace Medical Concepts' EBITDA Margin crashed by -379000bps in 2022 and then soared by 278700bps in 2023.
  • Treace Medical Concepts' EBITDA Margin (Quarter) stood at 16.74% in 2021, then skyrocketed by 47bps to 8.92% in 2022, then dropped by -8bps to 9.6% in 2023, then skyrocketed by 91bps to 0.87% in 2024, then plummeted by -3638bps to 32.37% in 2025.
  • Its last three reported values are 32.37% in Q3 2025, 36.73% for Q2 2025, and 30.36% during Q1 2025.